ClinicalEFFICACY OF thiethylperazine (cas 1420-55-9) AS A RECOVERY ROOM ANTI-EMETIC

Add time:09/30/2019    Source:sciencedirect.com

SUMMARYOf approximately 3,500 recovery room patients, 5 per cent vomited one or more times. Either thiethylperazine (cas 1420-55-9) or placebo was then administered in double-blind style, and both agents were approximately 60 per cent successful after one injection. However, 56 per cent of a similar series of (untreated) recovery room patients vomited only once. Of those vomiting twice, 30 per cent were successfully treated, a significantly higher success rate resulting from the use of thiethylperazine. Only 4 per cent of those vomiting three times stopped after drug administration. Since almost two-thirds of the victims vomited once only and one-fourth persisted despite continued therapy, only 15 per cent of all recovery room vomiters (1 per cent of all patients entering the recovery room) demonstrated the superiority of the active agent over saline. It is suggested that active therapy be delayed in recovery room vomiting until the second vomiting incident, and that for those who persist a physiologic aberration be sought and that either this be corrected or a search for a more potent anti-emetic be initiated.

We also recommend Trading Suppliers and Manufacturers of thiethylperazine (cas 1420-55-9). Pls Click Website Link as below: cas 1420-55-9 suppliers

Prev:An assessment of thiethylperazine (cas 1420-55-9) (Torecan) in the control of radiation-induced nausea and vomiting
Next:A radioimmunoassay for deoxycorticosterone sulfate (cas 1420-82-2) without hydrolysis)